Moderna’s (MRNA) forward visibility is starting to firm up and its Covid-19 revenue projections disappoint, but realistic in our view, notes Hartaj Singh. He discusses the state of the biotech market as MRNA shares hit a 3-year low last week. He talks about how MRNA’s spending, and margin pressure are still and issue. He also goes over Vertex Pharmaceuticals (VRTX) which is at a new 52-week high. He then looks at Regeneron (REGN) whose shares are up 15% year-to-date. Tune in to find out more about the stock market today.